公开(公告)号：US20210260089A1

公开(公告)日：2021-08-26

申请号：US17256807

申请日：2019-06-28

申请人： SHANGHAI GREEN VALLEY PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Meiyu Geng ,  Xianliang Xin ,  Xiaoguang Du ,  Zhenqing Zhang ,  Jian Ding

IPC分类号： A61K31/7032 ,  A61K31/716 ,  A61P25/16

摘要： The present invention relates to the use of mannuronic diacid oligosaccharide composition in the treatment of Parkinson's disease.

公开(公告)号：US20210221807A1

公开(公告)日：2021-07-22

申请号：US17057199

申请日：2019-05-21

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong LIU ,  Meiyu GENG ,  Yu ZHOU ,  Jian DING ,  Feifei FANG ,  Jing AI ,  Jian LI ,  Xia PENG ,  Hualiang JIANG ,  Yinchun JI ,  Kaixian CHEN

IPC分类号： C07D471/04 ,  C07D519/00

摘要： Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (with each group defined in the description). The compound can be used as an AXL inhibitor in the preparation of a pharmaceutical composition for treating tumors.

公开(公告)号：US20210214447A1

公开(公告)日：2021-07-15

申请号：US17055499

申请日：2019-05-10

申请人： FUDAN UNIVERSITY ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Ke YU ,  Jingkang SHEN ,  Tao MENG ,  Jinpeng PEI ,  Lanping MA ,  Xin WANG ,  Rui JIN ,  Zhiyan DU ,  Lin CHEN ,  Ting YU ,  Yongliang ZHANG

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61K45/06 ,  A61P35/00

摘要： Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified humanAXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.

公开(公告)号：US11013745B2

公开(公告)日：2021-05-25

申请号：US16651510

申请日：2018-08-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing Zhou ,  Cheng Luo ,  Yaxi Yang ,  Yuanyuan Zhang ,  Daohai Du ,  Hualiang Jiang ,  Gang Qiao ,  Xinjun Wang

IPC分类号： A61K31/519 ,  C07D487/04

摘要： The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.

公开(公告)号：US10968215B2

公开(公告)日：2021-04-06

申请号：US16331090

申请日：2017-09-06

申请人： SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Xuxing Chen ,  Meiyu Geng ,  Lei Jiang ,  Yi Chen ,  Jianhua Cao ,  Qingyun Jiang ,  Qianqian Shen ,  Jian Ding ,  Yucai Yao ,  Zhao Zhao ,  Yuanfang Xiong

IPC分类号： C07D471/04 ,  A61K31/5377 ,  A61K31/444 ,  A61P35/00 ,  A61K31/4545 ,  A61K31/496 ,  A61P37/06 ,  C07D519/00

摘要： The present invention provides a pyrido five-element aromatic ring compound, and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases.

公开(公告)号：US10966996B2

公开(公告)日：2021-04-06

申请号：US15126676

申请日：2015-03-17

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES ,  NANJING PAILEXING PHARMACEUTICAL TECHNOLOGY LTD.

发明人： Weiliang Zhu ,  Heyao Wang ,  Yong Zhang ,  Peng Sun ,  Bo Li ,  Zhijian Xu ,  Hualiang Jiang ,  Kaixian Chen

IPC分类号： A61K36/00 ,  A61K31/7048 ,  A61K36/53

摘要： Disclosed is a Glechoma longituba (Nakai) Kupr. extract, specifically compounds I and II, a preparation method for same, and a use thereof in preparing a medicament for blood glucose decease, blood lipids decrease, weight loss, and kidney disease treatment or a method for treatment of said diseases, and a composition containing the extract.

公开(公告)号：US10682352B2

公开(公告)日：2020-06-16

申请号：US16087556

申请日：2017-03-21

申请人： SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Lei Jiang ,  Meiyu Geng ,  Qiangang Zheng ,  Min Huang ,  Huixin Wan ,  Shuai Tang ,  Xianlei Fu ,  Xiaojing Lan ,  Jianhua Cao ,  Feifei Liu ,  Jian Ding

IPC分类号： A61K31/506 ,  A61P35/00 ,  A61P35/02 ,  C07D403/04 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14 ,  C07D401/14 ,  C07D405/14

摘要： Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

公开(公告)号：US10562900B2

公开(公告)日：2020-02-18

申请号：US15504854

申请日：2015-08-19

申请人： Shanghai Haihe Pharmaceutical Co., Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

发明人： Meiyu Geng ,  Lei Liu ,  Lei Jiang ,  Min Huang ,  Chuantao Zha ,  Jing Ai ,  Lei Wang ,  Jianhua Cao ,  Jian Ding

IPC分类号： C07D487/04 ,  C07D231/56 ,  C07D519/00 ,  C07D401/12 ,  C07D471/04 ,  C07D403/12 ,  C07D498/04 ,  C07D401/14 ,  C07D405/14 ,  C07D417/12 ,  A61K31/416 ,  A61K31/496

摘要： The present invention provides an indazole compound as a FGFR kinase inhibitor, preparation and use thereof. Specifically, the present invention provides a compound represented by formula (I), wherein the definitions of each group are described in the specification. The compound of the present invention has good FGFR kinase-inhibiting activity, and can be used in preparing a series of medicines for treating FGFR kinase activity related diseases.

公开(公告)号：US10550143B2

公开(公告)日：2020-02-04

申请号：US15738675

申请日：2016-06-23

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Hong Liu ,  Jia Li ,  Jiang Wang ,  Jingya Li ,  Hui Chen ,  Dan Li ,  Jian Li ,  Yibing Wang ,  Hualiang Jiang ,  Kaixian Chen

IPC分类号： C07H19/01 ,  A61P3/08

摘要： C, O-spiro aryl glycoside compounds are provided. Specifically provided are C, O-spiro aryl glycoside compounds represented by the formula (I), wherein the definitions of each variable group are described in the specification. Also provided are methods of preparing and using the C, O-spiro aryl glycoside compounds. The C, O-spiro aryl glycoside compounds can be used as SGLT2 inhibitors and for treating diseases, such as diabetes, atherosclerosis, and adiposity.

公开(公告)号：US20190382400A9

公开(公告)日：2019-12-19

申请号：US16251486

申请日：2019-01-18

申请人： Yushe Yang ,  Liang Tan ,  Qunhuan Kou

发明人： Yushe Yang ,  Liang Tan ,  Qunhuan Kou

IPC分类号： C07D417/14 ,  A61P31/04

摘要： The present disclosure relates to the field of pharmaceutical synthesis, and more particularly, relates to a monocyclic β-lactam-siderophore conjugate as well as a method for synthesizing same and its use in the treatment of bacterial infectious diseases. Provided are a monocyclic β-lactam-siderophore conjugate represented by formula (I) as described herein, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a method for synthesizing same, and a use thereof in treating bacterial infectious diseases.